When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, ...

New research maps the global burden of male cancers from 1990 to 2040, showing how aging, lifestyle, and healthcare access ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Cancer a life-threatening disease can spread or metastasise from its original location to other parts of the body The lungs ...

Nubeqa plus ADT improved rPFS in mHSPC regardless of disease volume, reducing the risk of radiological progression or death ...

2025 — A new study shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study suggests ... Inherited Gene Elevates Prostate ...

Delcath Systems, Inc. ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an update to the ...

Adding radium-223 to enzalutamide significantly improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases. The FDA has approved FoundationOne CDx ...